These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10423120)

  • 1. Cost-effectiveness analysis in the treatment of hypertension: a medical view.
    Whitworth J; Lang D; Henry D
    Clin Exp Hypertens; 1999; 21(5-6):999-1008. PubMed ID: 10423120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspective.
    Szucs TD; Waeber B; Tomonaga Y
    J Hum Hypertens; 2010 Feb; 24(2):117-23. PubMed ID: 19536166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
    Jönsson B; Hansson L; Stålhammar NO
    J Intern Med; 2003 Apr; 253(4):472-80. PubMed ID: 12653877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?
    Mullins CD; Blak BT; Akhras KS
    Value Health; 2002; 5(4):359-71. PubMed ID: 12102698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
    Soto M; Sampietro-Colom L; Sagarra J; Brugada-Terradellas J
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):563-71. PubMed ID: 26907729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of antihypertensive drugs: a perspective on medical innovation.
    Cutler DM; Long G; Berndt ER; Royer J; Fournier AA; Sasser A; Cremieux P
    Health Aff (Millwood); 2007; 26(1):97-110. PubMed ID: 17211019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New treatment strategies for the management of hypertension].
    Reinhardt A; Linsel-Nitschke P; Schunkert H
    MMW Fortschr Med; 2009 Nov; 151(46):33-6. PubMed ID: 20043391
    [No Abstract]   [Full Text] [Related]  

  • 9. Antihypertensive therapy: how to evaluate the benefits.
    Zanchetti A
    Am J Cardiol; 1997 May; 79(10A):3-8; discussion 47-8. PubMed ID: 9186060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic factors in the initiation of antihypertensive therapy.
    Kawachi I
    Pharmacoeconomics; 1992 Oct; 2(4):324-34. PubMed ID: 10147045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of arterial hypertension: benefits, costs, challenges].
    Zanchetti A
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():75S-81S. PubMed ID: 9004827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
    Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
    J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness issues in hypertension control.
    Schueler K
    Can J Public Health; 1994; 85 Suppl 2():S54-6. PubMed ID: 7804952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD; and Dominic Hodgkin, PhD.
    Am J Manag Care; 1998 Dec; 4(12 Suppl):S765-9; discussion S770. PubMed ID: 10339108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost effectiveness of hypertension treatment in Sweden.
    Johannesson M
    Pharmacoeconomics; 1995 Mar; 7(3):242-50. PubMed ID: 10155314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
    Elliott WJ; Weir DR; Black HR
    Arch Intern Med; 2000 May; 160(9):1277-83. PubMed ID: 10809030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of hypertension treatment.
    Ménard J
    Clin Exp Hypertens; 1996; 18(3-4):399-413. PubMed ID: 8743030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treating hypertension only in case of high risk? Evidence-based therapy with cost control].
    Trenkwalder P
    MMW Fortschr Med; 2001 Feb; 143(7):45-6. PubMed ID: 11268751
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.